SA
Create Free Alerts
Innoviva, Inc.INVANASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
businesswire.com

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year's report. The AMR Benchmark evaluates ph.

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
businesswire.com

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted select corporate progress and achievements. “202.

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
businesswire.com

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at.

SG Americas Securities LLC Raises Position in Innoviva, Inc. $INVA
defenseworld.net

SG Americas Securities LLC Raises Position in Innoviva, Inc. $INVA

SG Americas Securities LLC grew its position in shares of Innoviva, Inc. (NASDAQ: INVA) by 134.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,079 shares of the biotechnology company's stock after buying an additional 28,141 shares during the

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
marketbeat.com

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Biotech companies provide the medical innovations and technological breakthroughs that improve healthcare and can achieve tremendous financial results in the process. However, these names also tend to be highly volatile as a result of the difficult and complex process associated with drug and medical device development as well as the hard-to-navigate regulatory environment.

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
businesswire.com

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENCE® (zoliflodacin) for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 35 kg. The development of NUZOLVENCE was part of a private, not-for-profit collaboration.

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea
businesswire.com

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational single-dose, oral antibiotic zoliflodacin for the treatment of uncomplicated urogenital gonorrhea in The Lancet. The trial was sponsored and led by the Company's not-for-profit partner, the Global Antibiotic Research & Development Partnership (GARDP). “Gonorrhea c.

Boston Partners Boosts Holdings in Innoviva, Inc. $INVA
defenseworld.net

Boston Partners Boosts Holdings in Innoviva, Inc. $INVA

Boston Partners lifted its position in shares of Innoviva, Inc. (NASDAQ: INVA) by 40.6% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 875,084 shares of the biotechnology company's stock after acquiring an additional 252,534 shares during the quarter. Boston Partners owned approximately 1.39% of

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference
businesswire.com

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference in New York, NY on Tuesday, December 2, 2025 a.

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress
businesswire.com

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2025, and highlighted select corporate progress and achievements. “Innoviva delivered strong t.

Antheia Appoints Eric d'Esparbes as Chief Financial Officer
prnewswire.com

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

d'Esparbes to lead Antheia's financial strategy as the company continues its global expansionand commercialization MENLO PARK, Calif. , Oct. 21, 2025 /PRNewswire/ --  Antheia , the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of Eric d'Esparbes as Chief Financial Officer.

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025
businesswire.com

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), will share new data on zoliflodacin during the Infectious Disease Society of America's IDWeek 2025 annual meeting in Atlanta, GA, October 19-22, 2025. Zoliflodacin is a first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhea. Three sets of data will be presented, including an oral presentation and two poster presentations: Poster Presentation P-120.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance